Selective loss of basal forebrain cholinergic neurons by 192 IgG-saporin is associated with decreased phosphorylation of Ser9 glycogen synthase kinase-3β

Journal of Neurochemistry

Volumn 95, Issue 1, 2005, Pages 263-272

  Hawkes, C ^a   Jhamandas, J H ^b   Kar, Satyabrata ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Akt kinase; Cell death; Cholinergic markers; Immunolesion; Lithium chloride; Tau phosphorylation

Indexed keywords

BIOCHEMICAL MARKER; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN G; IMMUNOTOXIN; LITHIUM CHLORIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SAPORIN; SERINE; TAU PROTEIN; TYROSINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL DEATH; CELL LOSS; CELL SURVIVAL; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; FOREBRAIN; GLUCOSE METABOLISM; HIPPOCAMPUS; IN VIVO STUDY; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHOLINERGIC AGENTS; CHOLINERGIC FIBERS; GLYCOGEN SYNTHASE KINASE 3; IMMUNOTOXINS; INJECTIONS, INTRAVENTRICULAR; LITHIUM CHLORIDE; MALE; N-GLYCOSYL HYDROLASES; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS;

ANIMALIA;

EID: 25644439973     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03363.x     Document Type: Article

References (48)

1. Alvarez G., Munoz-Montano J. R., Satrustegui J., Avila J., Bogone Z. E. and Diaz-Nido J. (2002) Regulation of tau phosphorylation and protection against β-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord. 4, 153-165.
2. Anderton B. H., Brion J., Couck A. et al. (1995) Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells. Neurobiol. Aging 16, 389-397.
3. Bhat R. V., Shanley J., Correll M. P., Fieles W. E., Keith R. A., Scott C. W. and Lee C. M. (2000) Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. USA 97, 11 074-11 079.
4. Bhat R., Xue Y., Berg S. et al. (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278, 45 937-45 945.
5. Browne S. E., Lin L., Mattsson A., Georgievska B. and Isacson O. (2001) Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits. Exp. Neurol. 170, 36-47.
6. Chuang D. M., Chen R. W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., Kanai H., Hough C., Hiroi T. and Leeds P. (2002) Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. 4, 129-136.
7. Cole A., Frame S. and Cohen P. (2004) Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J. 377, 249-255.
8. Cross D. A., Culbert A. A., Chalmers K. A., Facci L., Skaper S. D. and Reith A. D. (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death. J. Neurochem. 77, 94-102.
9. De Ferrari G. V., Chacon M. A., Barria M. I., Garrido J. L., Godoy J. A., Olivares G., Reyes A. E., Alvarez A., Bronfman M. and Inestrosa N. C. (2003) Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils. Mol. Psychiatry 8, 195-208.
10. Doble B. W. and Woodgett J. R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186.
11. Frame S. and Cohen P. (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16.
12. Francis P. T., Palmer A. M., Snape M. and Wilcock G. K. (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66, 137-147.
13. Garrido J. L., Godoy J. A., Alvare Z. A., Bronfman M. and Inestrosa N. C. (2002) Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 16, 1982-1984.
14. Grimes C. A. and Jope R. S. (2001) The multifacted roles of glycogen synthase kinase 3β in cellular signaling. Prog. Neurobiol. 65, 391-426.
15. Harwood A. J. and Agam G. (2003) Search for a common mechanism of mood stabilizers. Biochem. Pharmacol. 66, 179-189.
16. Hawkes C. and Kar S. (2003) Insulin-like growth factor-II/mannose-6- phosphate receptor: widespread distribution in neurons of the central nervous system including those expressing cholinergic phenotype. J. Comp. Neurol. 458, 113-127.
17. Heckers S., Ohtake T., Wiley R. G., Lappi D. A., Geula C. and Mesulam M. M. (1994) Complete and selective cholinergic denervation of rat neocortex and hippocampus but not amygdala by an immunotoxin against the p75 NGF receptor. J. Neurosci. 14, 1271-1289.
18. Hernandez F., Borrell J., Guaza C., Avila J. and Lucas J. J. (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 83, 1529-1533.
19. Holtzman D. M., Kilbridge J., Li Y., Cunningham E. T., Lenn N. J., Clary D. O., Reichardt L. F. and Mobley W. C. (1995) TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons. J. Neurosci. 15, 1567-1576.
20. Inouye M., Yamamura H. and Nakano A. (1995) Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum. J. Radiat. Res. (Tokyo) 36, 203-208.
21. Jackson G. R., Wiedau-Pazos M., Sang T. K., Wagle N., Brown C. A., Massachi S. and Geschwind D. H. (2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509-519.
22. Jope R. S. (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24, 441-443.
23. Jope R. S. and Bijur G. N. (2002) Mood stabilizers, glycogen synthase kinase-3β and cell survival. Mol. Psychiatry 7, S35-S45.
24. Jope R. S. and Johnson G. V. W. (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Neurosci. 29, 95-102.
25. Kaplan D. R. and Miller F. D. (2000) Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10, 381-391.
26. Kar S. (2002) Role of amyloid β peptides in the regulation of central cholinergic functions and its relevance to Alzheimer's disease pathology. Drug Dev. Res. 56, 248-263.
27. Kaytor M. D. and Orr H. T. (2002) The GSK-3β signaling cascade and neurodegenerative disease. Curr. Opin. Neurobiol. 12, 275-278.
28. Kohn A. D., Summers S. A., Birnbaum M. J. and Roth R. A. (1996) Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 271, 31 372-31 378.
29. Lucas J. J., Hernandez F., Gomez-Ramos P., Moran M. A., Hen R. and Avila J. (2001) Decreased nuclear beta-catenin, tau phosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
30. Manji H. K., Moore G. J. and Chen G. (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J. Clin. Psychiatry 61, 82-96.
31. Pap M. and Cooper G. M. (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 273, 19 929-19 932.
32. Pascual T. and Gonzalez J. L. (1995) A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Brain Res. 695, 289-292.
33. Pei J. J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B. and Cowburn R. F. (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58, 1010-1019.
34. Perry T., Hodges H. and Gray J. A. (2001) Behavioural, histological and immunocytochemical consequences following 192 IgG-saporin immunolesions of the basal forebrain cholinergic system. Brain Res. Bull. 54, 29-48.
35. Rossner S. (1997) Cholinergic immunolesions by 192 IgG-saporin - useful tool to simulate pathogenic aspects of Alzheimer's disease. Int. J. Dev. Neurosci. 15, 835-850.
36. Ryves W. J. and Harwood A. J. (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 280, 720-725.
37. Selkoe D. J. and Schenk D. (2003) Alzheimer's disease: molecular understanding predicts amyloid based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545-584.
38. Shaw M., Cohen P. and Alessi D. R. (1997) Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett. 416, 307-311.
39. Su Y., Ryder J., Li B. et al. (2004) Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43, 6899-6908.
40. Takashima A., Noguchi K., Sato K., Hoshino T. and Imahori K. (1993) Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl Acad. Sci. USA 90, 7789-7793.
41. Thinakaran G. (1999) The role of presenilins in Alzheimer's disease. J. Clin. Invest. 104, 1321-1327.
42. Torres E. M., Perry T. A., Blockland A., Wilkinson L. S., Wiley R. G., Lappi D. A. and Dunnet S. B. (1994) Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience 63, 95-122.
43. Wei H., Qin Z. H., Senatorov V. V., Wei W., Wang Y., Qian Y. and Chuang D. M. (2001) Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106, 603-612.
44. Wiley R. G. (2001) Toxin-induced death of neurotrophin-sensitive neurons. Methods Mol. Biol. 169, 217-222.
45. Williams R., Ryves W. J., Dalton E. C., Eickholt B., Shaltiel G., Agam G. and Harwood A. J. (2004) A molecular cell biology of lithium. Biochem. Soc. Trans. 32, 799-802.
46. Wortwein G., Yu J., Toliver-Kinsky T. and Perez-Polo J. R. (1998) Responses of young and aged rat CNS to partial cholinergic immunolesions and NGF treatment. J. Neurosci. Res. 52, 322-333.
47. Xu J., Culman J., Blume A., Brecht S. and Gohlke P. (2003) Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 34, 1287-1292.
48. Zheng W H., Bastianetto S., Mennicken F., Ma W. and Kar S. (2002) Amyloid β peptide induces tau phosphorylation and neuronal degeneration in rat primary septal cultured neurons. Neuroscience 115, 201-211.